Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Restless Legs Syndrome.

Current treatment options in neurology

Lesage S, Earley CJ.
PMID: 15043804
Curr Treat Options Neurol. 2004 May;6(3):209-219. doi: 10.1007/s11940-004-0013-8.

In the past 10 years, restless legs syndrome (RLS) has gained recognition as a common sleep disorder. There are several therapeutic options in treating patients with RLS. RLS causes significant sleep disturbance and negatively impacts on patient quality of...

Cite
Lesage S, Earley CJ. Restless Legs Syndrome. Curr Treat Options Neurol. 2004;6(3):209-219doi: 10.1007/s11940-004-0013-8.
Lesage, S., & Earley, C. J. (2004). Restless Legs Syndrome. Current treatment options in neurology, 6(3), 209-219. https://doi.org/10.1007/s11940-004-0013-8
Lesage, Suzanne, and Earley, Christopher J.. "Restless Legs Syndrome." Current treatment options in neurology vol. 6,3 (2004): 209-219. doi: https://doi.org/10.1007/s11940-004-0013-8
Lesage S, Earley CJ. Restless Legs Syndrome. Curr Treat Options Neurol. 2004 May;6(3):209-219. doi: 10.1007/s11940-004-0013-8. PMID: 15043804.
Copy Download .nbib Format: NLM
Speed of response to dopaminergic agents in prolactinomas.

Endocrine

Hage C, Salvatori R.
PMID: 34846682
Endocrine. 2021 Nov 30; doi: 10.1007/s12020-021-02953-1. Epub 2021 Nov 30.

PURPOSE: Hyperprolactinemia in the presence of a sellar lesion can be caused by prolactin secretion from the lesion, or by increased intrasellar pressure/compression of the pituitary stalk ("stalk effect"). The objective of this work was to determine the response...

Cite
Hage C, Salvatori R. Speed of response to dopaminergic agents in prolactinomas. Endocrine. 2021;doi: 10.1007/s12020-021-02953-1.
Hage, C., & Salvatori, R. (2021). Speed of response to dopaminergic agents in prolactinomas. Endocrine, . https://doi.org/10.1007/s12020-021-02953-1
Hage, Camille, and Salvatori, Roberto. "Speed of response to dopaminergic agents in prolactinomas." Endocrine vol. (2021). doi: https://doi.org/10.1007/s12020-021-02953-1
Hage C, Salvatori R. Speed of response to dopaminergic agents in prolactinomas. Endocrine. 2021 Nov 30; doi: 10.1007/s12020-021-02953-1. Epub 2021 Nov 30. PMID: 34846682.
Copy Download .nbib Format: NLM
Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study.

Iranian journal of neurology

Rukmini Mridula K, Borgohain R, Jabeen SA, Padmaja G, Bandaru VS, Ankathi P, Kanikannan MA, Ali Khan MS.
PMID: 26056553
Iran J Neurol. 2015 Apr 04;14(2):86-93.

BACKGROUND: Non motor symptoms (NMS) of idiopathic Parkinson's disease (PD) are a major cause of disability and recognition of these symptoms and treatment is important for comprehensive health care. Deep brain stimulation of bilateral subthalamic nucleus deep brain stimulation...

Cite
Rukmini Mridula K, Borgohain R, Jabeen SA, et al. Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study. Iran J Neurol. 2015;14(2):86-93
Rukmini Mridula, K., Borgohain, R., Jabeen, S. A., Padmaja, G., Bandaru, V. S., Ankathi, P., Kanikannan, M. A., & Ali Khan, M. S. (2015). Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study. Iranian journal of neurology, 14(2), 86-93.
Rukmini Mridula, Kandadai, et al. "Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study." Iranian journal of neurology vol. 14,2 (2015): 86-93.
Rukmini Mridula K, Borgohain R, Jabeen SA, Padmaja G, Bandaru VS, Ankathi P, Kanikannan MA, Ali Khan MS. Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study. Iran J Neurol. 2015 Apr 04;14(2):86-93. PMID: 26056553; PMCID: PMC4449399.
Copy Download .nbib Format: NLM
"Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemic.

Journal of systems and integrative neuroscience

Blum K, Modestino EJ, Gondré-Lewis M, Downs BW, Baron D, Steinberg B, Siwicki D, Giordano J, McLaughlin T, Neary J, Hauser M, Fried L, Badgaiyan RD.
PMID: 30197787
J Syst Integr Neurosci. 2017 Nov;3(6). doi: 10.15761/JSIN.1000183. Epub 2017 Nov 17.

The well-researched pro-dopamine regulator KB220 and variants result in increased functional connectivity in both animal and human brains, and prolonged neuroplasticity (brain cell repair) having been observed in rodents. Moreover, in addition to increased functional connectivity, recent studies show...

Cite
Blum K, Modestino EJ, Gondré-Lewis M, et al. "Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemic. J Syst Integr Neurosci. 2017;3(6)doi: 10.15761/JSIN.1000183.
Blum, K., Modestino, E. J., Gondré-Lewis, M., Downs, B. W., Baron, D., Steinberg, B., Siwicki, D., Giordano, J., McLaughlin, T., Neary, J., Hauser, M., Fried, L., & Badgaiyan, R. D. (2017). "Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemic. Journal of systems and integrative neuroscience, 3(6), . https://doi.org/10.15761/JSIN.1000183
Blum, Kenneth, et al. ""Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemic." Journal of systems and integrative neuroscience vol. 3,6 (2017). doi: https://doi.org/10.15761/JSIN.1000183
Blum K, Modestino EJ, Gondré-Lewis M, Downs BW, Baron D, Steinberg B, Siwicki D, Giordano J, McLaughlin T, Neary J, Hauser M, Fried L, Badgaiyan RD. "Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemic. J Syst Integr Neurosci. 2017 Nov;3(6). doi: 10.15761/JSIN.1000183. Epub 2017 Nov 17. PMID: 30197787; PMCID: PMC6128292.
Copy Download .nbib Format: NLM
Gabapentin enacarbil: pharmacotherapy of restless legs syndrome.

Journal of central nervous system disease

Jones R, Rickards H, Cavanna AE.
PMID: 23861631
J Cent Nerv Syst Dis. 2010 Nov 23;2:45-55. doi: 10.4137/JCNSD.S4886. Print 2010.

Restless Legs Syndrome (RLS) is a prevalent sleep-associated movement disorder greatly affecting patients' quality of life (QoL). Several drugs can be used to control this condition although the first-line dopamine agents often cause adverse effects. Non-dopaminergic drugs such as...

Cite
Jones R, Rickards H, Cavanna AE. Gabapentin enacarbil: pharmacotherapy of restless legs syndrome. J Cent Nerv Syst Dis. 2010;2:45-55doi: 10.4137/JCNSD.S4886.
Jones, R., Rickards, H., & Cavanna, A. E. (2010). Gabapentin enacarbil: pharmacotherapy of restless legs syndrome. Journal of central nervous system disease, 245-55. https://doi.org/10.4137/JCNSD.S4886
Jones, Ruth, et al. "Gabapentin enacarbil: pharmacotherapy of restless legs syndrome." Journal of central nervous system disease vol. 2 (2010): 45-55. doi: https://doi.org/10.4137/JCNSD.S4886
Jones R, Rickards H, Cavanna AE. Gabapentin enacarbil: pharmacotherapy of restless legs syndrome. J Cent Nerv Syst Dis. 2010 Nov 23;2:45-55. doi: 10.4137/JCNSD.S4886. Print 2010. PMID: 23861631; PMCID: PMC3661230.
Copy Download .nbib Format: NLM
The dopamine hypothesis of drug addiction and its potential therapeutic value.

Frontiers in psychiatry

Diana M.
PMID: 22144966
Front Psychiatry. 2011 Nov 29;2:64. doi: 10.3389/fpsyt.2011.00064. eCollection 2011.

Dopamine (DA) transmission is deeply affected by drugs of abuse, and alterations in DA function are involved in the various phases of drug addiction and potentially exploitable therapeutically. In particular, basic studies have documented a reduction in the electrophysiological...

Cite
Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry. 2011;2:64doi: 10.3389/fpsyt.2011.00064.
Diana, M. (2011). The dopamine hypothesis of drug addiction and its potential therapeutic value. Frontiers in psychiatry, 264. https://doi.org/10.3389/fpsyt.2011.00064
Diana, Marco. "The dopamine hypothesis of drug addiction and its potential therapeutic value." Frontiers in psychiatry vol. 2 (2011): 64. doi: https://doi.org/10.3389/fpsyt.2011.00064
Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry. 2011 Nov 29;2:64. doi: 10.3389/fpsyt.2011.00064. eCollection 2011. PMID: 22144966; PMCID: PMC3225760.
Copy Download .nbib Format: NLM
Pentadecapeptide BPC 157 and the central nervous system.

Neural regeneration research

Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P.
PMID: 34380875
Neural Regen Res. 2022 Mar;17(3):482-487. doi: 10.4103/1673-5374.320969.

We reviewed the pleiotropic beneficial effects of the stable gastric pentadecapeptide BPC 157, three very recent demonstrations that may be essential in the gut-brain and brain-gut axis operation, and therapy application in the central nervous system disorders, in particular....

Cite
Vukojevic J, Milavić M, Perović D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487doi: 10.4103/1673-5374.320969.
Vukojevic, J., Milavić, M., Perović, D., Ilić, S., Čilić, A. Z., Đuran, N., Štrbe, S., Zoričić, Z., Filipčić, I., Brečić, P., Seiverth, S., & Sikirić, P. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural regeneration research, 17(3), 482-487. https://doi.org/10.4103/1673-5374.320969
Vukojevic, Jakša, et al. "Pentadecapeptide BPC 157 and the central nervous system." Neural regeneration research vol. 17,3 (2022): 482-487. doi: https://doi.org/10.4103/1673-5374.320969
Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022 Mar;17(3):482-487. doi: 10.4103/1673-5374.320969. PMID: 34380875; PMCID: PMC8504390.
Copy Download .nbib Format: NLM
Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease.

Frontiers in human neuroscience

Cui CK, Lewis SJG.
PMID: 34795568
Front Hum Neurosci. 2021 Nov 02;15:741918. doi: 10.3389/fnhum.2021.741918. eCollection 2021.

Freezing of gait (FOG) is a common and challenging clinical symptom in Parkinson's disease. In this review, we summarise the recent insights into freezing of gait and highlight the strategies that should be considered to improve future treatment. There...

Cite
Cui CK, Lewis SJG. Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease. Front Hum Neurosci. 2021;15:741918doi: 10.3389/fnhum.2021.741918.
Cui, C. K., & Lewis, S. J. G. (2021). Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease. Frontiers in human neuroscience, 15741918. https://doi.org/10.3389/fnhum.2021.741918
Cui, Cathy K, and Lewis, Simon J G. "Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease." Frontiers in human neuroscience vol. 15 (2021): 741918. doi: https://doi.org/10.3389/fnhum.2021.741918
Cui CK, Lewis SJG. Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease. Front Hum Neurosci. 2021 Nov 02;15:741918. doi: 10.3389/fnhum.2021.741918. eCollection 2021. PMID: 34795568; PMCID: PMC8592896.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries